---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-033196"
form_type: "8-K"
ticker: "LRMR"
cik: "0001374690"
company_name: "Larimar Therapeutics, Inc."
filed_at: "2023-07-17T23:59:59+00:00"
generated_at: "2026-06-13T07:31:37.095125+00:00"
event_type: "leadership"
sentiment: "neutral"
materiality_score: 0.55
calibrated_materiality_score: 0.55
confidence: "high"
source: SEC EDGAR
---

# Larimar Therapeutics appoints Russell Clayton as CMO, 180K stock option inducement grant

## Summary
- Russell 'Rusty' Clayton appointed Chief Medical Officer effective July 17, 2023, succeeding Nancy M. Ruiz (retiring).
- Dr. Clayton previously served as Principal at Aeremedea, LLC and as advisor to Larimar for 5 years.
- Inducement award of 180,000 stock options granted under Nasdaq Listing Rule 5635(c)(4), vesting over 4 years.
- Dr. Clayton brings ~20 years of rare disease experience, including roles at Alcresta Therapeutics and Merck.

## SEC filing metadata
- accession: 0000950170-23-033196
- form_type: 8-K
- ticker: LRMR
- cik: 0001374690
- company_name: Larimar Therapeutics, Inc.
- filed_at: 2023-07-17T23:59:59+00:00
- event_type: leadership
- sentiment: neutral
- materiality_score: 0.55
- calibrated_materiality_score: 0.55
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/0000950170-23-033196-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1374690/000095017023033196/lrmr-20230717.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-033196
- JSON: https://secwatch.observer/filing/0000950170-23-033196.json
- Plain text: https://secwatch.observer/filing/0000950170-23-033196.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.